↓ Skip to main content

Dove Medical Press

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TPN171H, a Novel Phosphodiesterase Type 5 Inhibitor, in Healthy Subjects

Overview of attention for article published in Drug Design, Development and Therapy, July 2021
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (57th percentile)
  • Good Attention Score compared to outputs of the same age and source (69th percentile)

Mentioned by

wikipedia
1 Wikipedia page

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
14 Mendeley
Title
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TPN171H, a Novel Phosphodiesterase Type 5 Inhibitor, in Healthy Subjects
Published in
Drug Design, Development and Therapy, July 2021
DOI 10.2147/dddt.s308610
Pubmed ID
Authors

Hongjie Qian, Qian Chen, Liyu Liang, Yang Zou, Huahua Pu, Liang Xin, Rong Song, Tingting Li, Huijuan Zhu, Yu Wang, Guanghui Tian, Jingshan Shen, Hualiang Jiang, Chen Yu, Zhen Wang, Jingying Jia

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 14 100%

Demographic breakdown

Readers by professional status Count As %
Student > Doctoral Student 2 14%
Lecturer 2 14%
Student > Postgraduate 2 14%
Researcher 2 14%
Other 1 7%
Other 0 0%
Unknown 5 36%
Readers by discipline Count As %
Medicine and Dentistry 4 29%
Pharmacology, Toxicology and Pharmaceutical Science 2 14%
Biochemistry, Genetics and Molecular Biology 2 14%
Nursing and Health Professions 1 7%
Unknown 5 36%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 November 2023.
All research outputs
#8,541,797
of 25,392,582 outputs
Outputs from Drug Design, Development and Therapy
#643
of 2,269 outputs
Outputs of similar age
#174,557
of 453,590 outputs
Outputs of similar age from Drug Design, Development and Therapy
#18
of 59 outputs
Altmetric has tracked 25,392,582 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,269 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 453,590 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 57% of its contemporaries.
We're also able to compare this research output to 59 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.